Salicylamide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Salicylamide: From Antipyretic/Analgesic Agent to Pharyngitis
One-Sentence Summary
Salicylamide is an older analgesic/antipyretic compound (DrugBank DB08797) with no original indication recorded in structured regulatory data, though historical literature documents its use for fever and pain relief, including direct treatment of childhood tonsillitis. The TxGNN model predicts it may be effective for pharyngitis, currently supported by 0 clinical trials and 3 publications, all dating from 1953–1969.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in structured regulatory data; historically used as an antipyretic/analgesic (per literature) |
| Predicted New Indication | Pharyngitis |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L3 |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, salicylamide is a non-acetylated salicylate derivative historically used as a general-purpose antipyretic and analgesic (as reflected in 1950s–60s clinical literature), and its efficacy in relieving fever and pain has been described, and mechanistically may be applicable to pharyngitis, where fever and throat pain are core symptoms.
Pharyngitis is frequently accompanied by fever and throat pain, symptoms that align directly with salicylamide’s known antipyretic-analgesic action. Notably, one historical report (PMID 13060598) describes direct clinical use of salicylamide (o-hydroxybenzamide) combined with sodium p-aminobenzoate for treating catarrhal tonsillitis in infants — this is symptomatic rather than causal treatment, but it provides real-world precedent rather than a purely computational association.
It should be emphasized that this evidence base predates modern clinical trial standards, and none of the identified literature is a contemporary controlled trial of salicylamide specifically in pharyngitis.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 5354503 | 1969 | Double-blind study | Minerva medica | Double-blind comparison of two bismuth preparations in pharyngo-tonsillitis (study drug was bismuth, not salicylamide itself) |
| 13060598 | 1953 | Clinical Study | Gazzetta medica italiana | Direct treatment of catarrhal tonsillitis in infancy with salicylamide (o-hydroxybenzamide) combined with sodium p-aminobenzoate |
| 14126993 | 1963 | Case Series | Kinderarztliche Praxis | Open experience report on a new antipyretic/analgesic in a rectal capsule formulation |
South Africa Market Information
Salicylamide currently has no SAHPRA registration on record (0 licenses) and is not marketed in South Africa. No registered product, dosage form, or approved indication information is available.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence supporting pharyngitis as a use for salicylamide is limited to three low-tier publications from 1953–1969, with no contemporary clinical trials and no controlled study of salicylamide itself in this indication. Critically, TFDA/SAHPRA labelling data (warnings and contraindications) are marked as a Blocking data gap, meaning this candidate cannot yet pass initial safety screening (S1), and the drug is not currently marketed in South Africa.
To proceed, the following is needed:
- SAHPRA-approved Professional Information (PI), including warnings and contraindications, to clear the blocking safety gap
- Confirmed mechanism of action (MOA) data from DrugBank or equivalent source
- Contemporary clinical evidence (post-2000) evaluating salicylamide specifically in pharyngitis
- Regulatory pathway assessment given the drug’s unregistered status in South Africa
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.